Effects of liposome-entrapped annamycin in human breast cancer cells: Interference with cell cycle progression and induction of apoptosis

Journal of Cellular Biochemistry

Volumn 81, Issue 1, 2001, Pages 9-22

  Orlandi, Linda ^a   Bertoli, Gloria ^a   Abolafio, Gabriella ^a   Daidone, Maria Grazia ^a   Zaffaroni, Nadia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Anthracyclines; cdc2 kinase; Cell proliferation; Flow cytometry; p53

Indexed keywords

ANNAMYCIN; ANTHRACYCLINE ANTIBIOTIC AGENT; CYCLIN B1; DOXORUBICIN; LIPOSOME; PROTEIN BAX; PROTEIN KINASE; PROTEIN P21;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DOSE RESPONSE; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSACTIVATION;

EID: 0035089655     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-4644(20010401)81:1<9::AID-JCB1020>3.0.CO;2-C     Document Type: Article

References (38)

1. cdc2 on Thr-14 and Tyr-15 at the prophase/metaphase transition
2. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix
3. Cdc2 regulatory factors
4. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: Comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines
5. cdc2 coincident with taxol-induced apoptosis
6. WAF1/CIP 1 is induced in p53-mediated G1 arrest and apoptosis
7. waf1/cip1 protects against p53-mediated apoptosis of human melanoma cells
8. Growth arrest and nonapoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin
9. The protein kinase C inhibitor ilmofosine (BM 41 440) arrests cells in G2 phase and suppresses CDC2 kinase activation through a mechanism different from that of DNA damaging agents
10. 2 checkpoint through cyclin B1
11. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[β-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells
12. Comparison of annamycin to adriamycin in cardiac and MDR tumor cell systems
13. Driving the cell cycle: M phase kinase, its partners, and substrates
14. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes
15. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells
16. Partial circumvention of multi-drug resistance by annamycin is associated with comparable inhibition of DNA synthesis in the nuclear matrix of sensitive and resistant cells
17. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells
18. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
19. waf1 in response of human breast cancer cell clones to Tomudex
20. Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cells
21. Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-1 cancer cell lines selected for resistance to etoposide
22. Anthracycline antibiotics with high liposome entrapment: Structural features and biological activity
23. Design and tumor targeting of anthracyclines able to overcome multidrug resistance: A double-advantage approach
24. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress
25. P53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells
26. Overexpression of p21 WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines
27. cdc2 activation required for apoptosis
28. Unscheduled activation of cyclin B1/cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage
29. Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells
30. s sensitizes MCF-7 cells to chemotherapy-induced apoptosis
31. Effects of estrogen on apoptotic pathways in human breast cancer cells line MCF-7
32. p21 is a universal inhibitor of cyclin kinases
33. cdc2 kinase
34. Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cancer cells
35. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties
36. Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the non-cross-resistant anthracycline annamycin incorporated in liposomes
37. Preclinical toxicity of liposome-incorporated annamycin: Selective bone marrow toxicity with lack of cardiotoxicity
38. Lyophilized preliposomal formulation of the non-cross-resistant anthracycline annamycin: Effect of surfactant on liposome formation, stability and size